These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34092344)

  • 21. The FDA Breakthrough-Drug Designation - Four Years of Experience.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical trial network for the promotion of clinical research for rare diseases in Japan: muscular dystrophy clinical trial network.
    Shimizu R; Ogata K; Tamaura A; Kimura E; Ohata M; Takeshita E; Nakamura H; Takeda S; Komaki H
    BMC Health Serv Res; 2016 Jul; 16():241. PubMed ID: 27401940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Italian program for independent research on drugs: 10 year follow-up of funded studies in the area of rare diseases.
    Traversa G; Masiero L; Sagliocca L; Trotta F
    Orphanet J Rare Dis; 2016 Apr; 11():36. PubMed ID: 27068647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Researchers facing increasing costs for clinical research, with few solutions.
    Erdmann J
    J Natl Cancer Inst; 2005 Oct; 97(20):1492-4. PubMed ID: 16234558
    [No Abstract]   [Full Text] [Related]  

  • 25. Ethical, legal and social implications of rare diseases and orphan drugs in Europe: meeting report of a Brocher symposium.
    Picavet E; Cassiman D; Pinxten W; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2013 Oct; 13(5):571-3. PubMed ID: 24138643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapeutic uses of investigational drugs: research extension, compassionate use, and expanded access].
    Goldim JR
    Rev Panam Salud Publica; 2008 Mar; 23(3):198-206. PubMed ID: 18397586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implications of pharmaceutical industry funding on clinical research.
    Lexchin JR
    Ann Pharmacother; 2005 Jan; 39(1):194-7. PubMed ID: 15562137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial.
    Crow RA; Hart KA; McDermott MP; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Hirtz D; Lochmuller H; Straub V; Ciafaloni E; Shieh PB; Spinty S; Childs AM; Manzur AY; Morandi L; Butterfield RJ; Horrocks I; Roper H; Flanigan KM; Kuntz NL; Mah JK; Morrison L; Darras BT; von der Hagen M; Schara U; Wilichowski E; Mongini T; McDonald CM; Vita G; Barohn RJ; Finkel RS; Wicklund M; McMillan HJ; Hughes I; Pegoraro E; Bryan Burnette W; Howard JF; Thangarajh M; Campbell C; Griggs RC; Bushby K; Guglieri M
    Trials; 2018 May; 19(1):291. PubMed ID: 29793540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of industry sponsorship to published outcomes in gastrointestinal clinical research.
    Brown A; Kraft D; Schmitz SM; Sharpless V; Martin C; Shah R; Shaheen NJ
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1445-51. PubMed ID: 17101295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. State payer mandates to cover care in US oncology trials: do science and ethics matter?
    Taylor PL
    J Natl Cancer Inst; 2010 Mar; 102(6):376-90. PubMed ID: 20197514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SIMD statement on investigational new drugs for rare disease therapies.
    Longo N
    Mol Genet Metab; 2012 Mar; 105(3):367. PubMed ID: 22300846
    [No Abstract]   [Full Text] [Related]  

  • 32. Industry funded clinical trials: bias and quality.
    Del Parigi A
    Curr Med Res Opin; 2012 Jan; 28(1):23-5. PubMed ID: 22103762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Donor-funded research: permissible, not perfect.
    King M; Ballantyne A
    J Med Ethics; 2019 Jan; 45(1):36-40. PubMed ID: 30228163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New Royal Decree on clinical trials: main implications for emergency medicine physicians who do research].
    García Arenillas M; Haj-Ali Saflo O; Sáenz de Tejada M
    Emergencias; 2017 Jun; 29(3):194-201. PubMed ID: 28825241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development.
    Miller KL; Mueller C; Liu G; Miller Needleman KI; Maynard J
    Orphanet J Rare Dis; 2020 Sep; 15(1):234. PubMed ID: 32883327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Not Available].
    Göpel W
    Drug Res (Stuttg); 2018 Nov; 68(S 01):S3. PubMed ID: 30453360
    [No Abstract]   [Full Text] [Related]  

  • 37. Managing physician financial conflicts of interest in clinical trials conducted in the private practice setting.
    Williams KM
    Food Drug Law J; 2004; 59(1):45-77. PubMed ID: 15190925
    [No Abstract]   [Full Text] [Related]  

  • 38. Dilemmas in the compassionate supply of investigational cancer drugs.
    Lewis JR; Lipworth W; Kerridge I; Doran E
    Intern Med J; 2014 Sep; 44(9):841-5. PubMed ID: 25201421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.
    Winstone J; Chadda S; Ralston S; Sajosi P
    Orphanet J Rare Dis; 2015 Oct; 10():139. PubMed ID: 26511061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Industry funding effect on positive results of probiotic use in the management of acute diarrhea: a systematized review.
    Saa C; Bunout D; Hirsch S
    Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):289-302. PubMed ID: 30557228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.